Integromics, has announced that it has extended its partnership with Ingenuity®, a provider of information and analytics solutions for life science researchers. The partnership extension involves the scheduled integration of Integromics’ fourth product, SeqSolve™ to offer the most complete collection of Omics tools integrated with Ingenuity’s IPA® software.
The SeqSolve analysis software, exclusively designed for Next Generation Sequencing (NGS), performs tertiary level analysis of RNA-seq data at the gene and transcript level for biologically relevant results. Integromics has already integrated three solutions with Ingenuity’s IPA: Integromics Biomarker Discovery® for microarray data analysis, RealTime StatMiner® for the analysis of qPCR data as well as OmicsHub® Proteomics for the analysis and storage of proteomics data.
Ingenuity’s technology differs from competitors in the automation API that allows integration with third-party tools, like Integromics’ SeqSolve. The combined solutions will enable users to go from the aligned sequences to the function, interactions, pathways and disease association of the genes or variant forms identified in the experiment.
Ingenuity gains access to the NGS and proteomics domains as well as a powerful suite of genomics tools and a proteomics tool tightly integrated with their pathway tool.
There has been increasing and significant demand for NGS technology in recent years. However, high-impact biological interpretation of NGS data sets has been limited. Currently, the vast majority of the existing tools for analyzing NGS data only reach secondary analysis with a complex user experience.
This is centered on the alignment of the sequence from the instrument against a reference without genome-wide profiling of biologically significant genomics features, nor advanced statistical support for differential gene expression.
“The integration of Integromics’ four products to Ingenuity’s IPA product provides greater information between the discovery of differentially expressed genes, novel or differential splice forms, proteins, and the clinical or medical relevance of the findings,” said Dr. Michael J. McManus, CEO, Integromics. “Integromics can offer the market a spectrum of coverage spanning from microarrays to NGS data and proteomics while providing a consistent interface to IPA’s pathway data and biological context in each of the Integromics products.”
“We are very pleased to work with Integromics to integrate IPA with SeqSolve,” said Doug Bassett, Ph.D., CSO and CTO, Ingenuity Systems. “Researchers with RNA-seq data will have a trusted and streamlined workflow to help them narrow in on what is most important in their data set and get to powerful biological insights.”